Is Seladelpar effective in treating primary biliary cholangitis?

Seladelpar is a selective peroxisome proliferator-activated receptor delta (PPARdelta) agonist, mainly used to treat primary biliary cholangitis (Primary Biliary Cholangitis, PBC). This drug helps improve cholestasis and reduce liver damage by regulating bile acid metabolism and reducing liver inflammatory response, thereby achieving therapeutic purposes.

In clinical trials, Siladepa showed significant efficacy. Multiple Phase II and Phase III clinical studies have shown that alkaline phosphatase (ALP) levels were significantly reduced in patients using Seradepa. This indicator is widely regarded as an important biomarker for evaluating PBC disease control. In addition, the patient's liver function and symptoms also improved to some extent, indicating that the drug can effectively alleviate disease progression.

Compared with traditional therapeutic drugs, such as ursodeoxycholic acid (UDCA) and bevacizumab (obeticholic acid), Siladepa has a unique mechanism of action in improving bile acid metabolism and reducing liver inflammation, with relatively fewer side effects and better tolerance. Therefore, Siladepa provides a new treatment option for PBC patients who do not respond well to traditional treatments.

However, although the current research results are encouraging, Siladepa is still in the stage of further verification of efficacy and safety, and more long-term clinical data are needed to support its widespread use. Patients should follow medical advice when using this drug and closely monitor liver function and related indicators to ensure the safety and effectiveness of treatment.

Reference materials:https://www.drugs.com/donanemab.html